Biosimilar Antibodies

Adintrevimab (ADG 20) is a human IgG1 monoclonal antibody specifically targeting the SARS-CoV (SARS-CoV) virus. This antibody demonstrates inhibitory activity against SARS-CoV-2 variants as well as other SARS-like coronaviruses that possess pandemic potential. This makes it a valuable tool for research into the prevention and treatment of current and future coronavirus outbreaks.

Benralizumab (MEDI-563) is a cytolytic monoclonal antibody that targets the interleukin-5 receptor α (IL-5Rα), facilitating direct, rapid, and near-complete depletion of eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). This agent is specifically designed for the treatment of severe eosinophilic asthma, offering a targeted therapeutic approach by modulating the eosinophilic inflammatory response that characterizes this condition.

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.

Etevritamab is a monoclonal antibody designed to target both CD3E and EGFR. This dual-specificity enables it to engage mechanisms related to T-cell activation and tumor cell inhibition, making it a valuable tool for research in immunotherapy and oncology. Etevritamab may be utilized in studies aiming to elucidate the pathways of immune response modulation and tumor growth suppression.

Ifinatamab is a monoclonal antibody of the immunoglobulin G1-kappa subclass, designed to target and inhibit the human B7 homolog 3 protein (B7-H3). This antibody functions as an immunomodulator, leveraging glycoengineering to enhance its efficacy and stability. Ifinatamab is specifically developed for its potential therapeutic applications in modulating immune responses against various pathological conditions where B7-H3 is implicated.

Barzolvolimab (CDX 0159) is a humanized IgG1 monoclonal antibody targeting the KIT receptor. It demonstrates specificity and potent inhibition of KIT activation mediated by the stem cell factor (SCF). Clinically, Barzolvolimab has been shown to effectively reduce skin mast cell populations and alleviate disease activity in chronic inducible urticaria, highlighting its potential therapeutic application in related pathologies.

ACT017 is a humanized Fab fragment of an anti-GPVI monoclonal antibody designed to inhibit collagen-induced platelet aggregation. This product is specifically developed for research applications focusing on acute ischemic stroke, providing a valuable tool for studies aimed at understanding and potentially intervening in platelet aggregation pathways during ischemic events.

Prafnosbart (DS-6016A) is a humanized monoclonal antibody of the IgG1-kappa isotype, targeting ACVR1 (also known as activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1). This antibody is specifically designed for the study of bone metabolism disorders, providing a crucial tool for researchers investigating the signaling pathways and regulatory mechanisms involved in bone development and maintenance.

Zemocimig is a human IgG4 κ monoclonal antibody targeting coagulation factor F9. For optimal experimental control, it is recommended to use Human IgG4 kappa Isotype Control.

Gresonitamab (AMG 910) is a half-life extended bispecific T-cell engager (BiTE) antibody designed to target CD3-positive T cells and tumor cells expressing CLDN18.2. This antibody facilitates the engagement and activation of T cells at tumor sites, enhancing the immune response against cancer cells. Gresonitamab is primarily utilized in research focused on adenocarcinoma, providing a valuable tool for investigating immune-based therapeutic strategies in this cancer type.

Umesolerbart (REGN5714) is a monoclonal antibody specifically targeting Bet v1, a major allergen from birch trees. This antibody exhibits cross-reactivity with homologous allergens found in alder, hazel, and hornbeam, making it an invaluable tool for studying cross-reactivity patterns in tree pollen allergies. Umesolerbart (REGN5714) is ideal for research applications focused on allergen characterization and the development of therapeutic strategies for pollen-induced allergic responses.

Racotumomab is a recombinant anti-idiotype monoclonal antibody that targets Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other tumor-associated antigens. This antibody has demonstrated efficacy as an active anticancer agent, particularly in the treatment of lung cancer. Its specificity for NeuGc epitopes makes it a valuable tool for research and therapeutic applications in oncology.

Spevatamig is a bispecific antibody of the (H-γ1_L-κ)_(H-γ1_L-κ) type, designed to target CD47 and CLDN18. This dual specificity facilitates its application in the selective targeting and inhibition of pathways crucial in cancer cell survival and immune evasion, making it a valuable tool for research in oncology and immunotherapy.

Tilavonemab (ABBV-8E12) is a humanized monoclonal antibody designed to target and neutralize extracellular pathological tau protein aggregates. It specifically binds to the N-terminal 25-30 amino acid residues of the tau protein. This interaction inhibits the uptake of tau aggregates by human and mouse neurons, mitigates brain volume loss, decelerates the progression of tau pathology, and enhances cognitive functions in transgenic mice models expressing mutant human tau. Tilavonemab is primarily utilized in research focused on Alzheimer's disease, offering significant insights into the mechanisms of tau-related neurodegeneration and potential therapeutic interventions.

The Anti-GC1q R/C1QBP Antibody (60.11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human GC1q R/C1QBP. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control alongside this antibody.

Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody that specifically targets the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody exhibits a high affinity for the extracellular domain of human TIM-3, with a dissociation constant (K_D) of 0.36 nM, indicating strong and specific binding. Surzebiclimab is primarily utilized in the research of cancer immunotherapy, exploring pathways for enhancing immune responses against tumors.

Ozoralizumab (ATN-103) is a humanized trivalent nanobody that targets tumor necrosis factor alpha (TNFα). Comprising two anti-human TNFα nanobodies and one anti-human serum albumin (HSA) nanobody, this antibody is engineered for enhanced stability and serum half-life. It is particularly relevant for research into inflammatory disorders, including various forms of arthritis, where TNFα plays a pivotal role in pathogenesis.

Atrosab is a humanized IgG1 monoclonal antibody that functions as an antagonist to tumor necrosis factor receptor 1 (TNFR1). It effectively inhibits TNF-alpha-mediated apoptosis and the production of interleukins IL-6 and IL-8, key mediators in inflammatory processes. This antibody has been shown to reduce neurological deficits, highlighting its potential utility in the study of neuroinflammation and other inflammatory diseases. For control experiments, the recommended isotype control is Human IgG1 kappa.

The Anti-CD40 Antibody (G28.5) is a chimeric mouse monoclonal antibody of the IgG1 kappa isotype, specifically designed to target human CD40. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is suitable for a range of immunological assays investigating the role of CD40 in immune responses and its implications in immunological research and therapeutic development.

TOL-101 is a monoclonal antibody that specifically targets the T-cell receptor (TCR). This antibody is designed for use in the study of T-cell mediated immune responses and may be utilized in various immunological assays to investigate TCR function and expression. TOL-101 is valuable for researchers focusing on cellular immunology, autoimmunity, and the development of immunotherapies.

Guselkumab is a recombinant human IgG1 monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). This antibody exhibits high affinity for IL-23, with dissociation constants (Kd) of 3.3 pmol/L for human IL-23 and 1.9 pmol/L for IL-23 derived from cynomolgus monkeys. By binding to the IL-23p19 subunit, Guselkumab effectively inhibits the production of cytokines that are downstream in the IL-23 signaling pathway. This mechanism of action makes Guselkumab particularly useful in the study of psoriatic arthritis, providing a valuable tool for research into the pathophysiology and potential treatment of this condition.

Xaluritamig is a monoclonal antibody designed to target both CD3E and STEAP1. This dual specificity allows for the potential engagement of immune system modulation through CD3E interaction and direct targeting of STEAP1, a protein implicated in several oncologic processes. Xaluritamig is primarily used in research focused on cancer immunotherapy and the study of immune response mechanisms.

Cliramitug is a monoclonal antibody that specifically targets human transthyretin (TTR). This antibody interacts with TTR, effectively inhibiting its propensity to form amyloid fibrils. By preventing amyloidogenesis, Cliramitug serves as a valuable tool in the study of transthyretin amyloidosis and its associated neurological and cardiovascular pathologies. This antibody is instrumental for researchers focusing on the molecular mechanisms and therapeutic interventions for TTR-related diseases.

Raludotatug is a humanized IgG1-kappa monoclonal antibody targeting CDH6, designed for antineoplastic applications. This therapeutic antibody binds specifically to CDH6, a protein implicated in the progression of certain cancers, thereby inhibiting tumor growth and proliferation. Raludotatug's mechanism of action and specificity make it a valuable tool for research and potential therapeutic interventions in oncology.

Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody targeting vimentin present on the surface of virus-infected cells. It exhibits broad-spectrum antiviral activity and possesses anti-inflammatory properties, specifically mitigating virus-induced inflammation. This antibody is particularly relevant for research focused on severe COVID-19, providing a critical tool for studies aimed at understanding and potentially mitigating the impact of viral infections.

CDX-1401 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets LY75/CD205/DEC-205, a receptor involved in antigen capture and presentation. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody designed for dual targeting of B-cell activating factor (BAFF) and interleukin-17A (IL-17A), exhibiting high affinity with dissociation constants (Kd) of 60 pM and 14 pM, respectively. This antibody is specifically engineered for the study of autoimmune diseases, providing a valuable tool for investigating the pathophysiological roles of BAFF and IL-17A in immune modulation and inflammation.

Brazikumab (AMG 139) is a human IgG2 monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23). It exhibits a high binding affinity with a dissociation constant (K_D) of 0.138 nM for human IL-23. This specificity makes Brazikumab a valuable tool for the study of immune-mediated inflammatory disorders, particularly Crohn's disease.

Paridiprubart (NI-0101) is a humanized monoclonal antibody that targets Toll-like receptor 4 (TLR4). This antibody has been developed for potential application in the research of rheumatoid arthritis, focusing on its role in modulating immune responses associated with the disease. Paridiprubart offers a valuable tool for investigating the pathophysiological mechanisms and therapeutic interventions for rheumatoid arthritis through its specific interaction with TLR4.

Toralizumab (IDEC-131) is a humanized monoclonal antibody targeting CD40 ligand (CD154), composed of human gamma 1 heavy chains and kappa light chains. This antibody selectively binds to CD40L expressed on T cells, effectively inhibiting CD40-mediated signaling. As an immunosuppressive agent, Toralizumab is primarily investigated for its therapeutic potential in systemic lupus erythematosus (SLE) research.

Onvatilimab (JNJ-61610588) is a human IgG1κ monoclonal antibody that targets VISTA (V-domain Ig Suppressor of T-cell Activation), a protein involved in the negative regulation of T-cell responses. This antibody exhibits potent anti-tumor activity by modulating the immune system's ability to recognize and destroy cancer cells. Onvatilimab is primarily researched for its therapeutic potential in oncology, particularly in enhancing immune-mediated tumor suppression.

Tecaginlimab (BNT-312) is an Fc-inert bispecific antibody engineered for the dual targeting and conditional stimulation of CD40 and 4-1BB receptors. This antibody is designed to enhance the priming and reactivation of tumor-specific immune responses, making it a valuable tool for research in cancer immunotherapy. Tecaginlimab's unique ability to engage both CD40 and 4-1BB under specific conditions allows for precise modulation of immune activation, potentially leading to improved therapeutic outcomes in oncology research.

Robatumumab (Sch 717454) is a monoclonal antibody targeting the insulin-like growth factor receptor-1 (IGF-1R). It exhibits potent anti-tumor and anti-proliferative effects on cancer cells. This antibody is particularly relevant for research in osteosarcoma and Ewing sarcoma, providing a valuable tool for investigating the role of IGF-1R in cancer pathogenesis and therapy.

The Anti-TLR3/CD283 Antibody (CNTO5429) is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets TLR3/CD283, a receptor involved in the innate immune response to viral double-stranded RNA. This antibody comprises a human IgG2 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.42 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

Vulinacimab (HLX-06) is a monoclonal antibody targeting VEGFR-2, a receptor overexpressed in various tumor types. This antibody is instrumental in studying the mechanisms of angiogenesis and the associated processes of proliferation, survival, migration, and differentiation of endothelial cells in cancer research. Vulinacimab provides a valuable tool for investigating the role of VEGFR-2 in oncological pathologies and therapeutic interventions.

Emfizatamab is a monoclonal antibody designed to target CD19, CD3E, TNFRSF9, and PD-L1. This multifunctional antibody facilitates the engagement of immune effector cells with cancer cells, potentially enhancing the immune response against malignant cells. It is primarily used in research focused on the mechanisms of immune modulation in oncology and the therapeutic potential in various cancers.

Burosumab is a human monoclonal antibody that selectively neutralizes fibroblast growth factor 23 (FGF23). This antibody is employed in the study of disorders such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia, offering significant insights into the pathophysiological mechanisms and potential therapeutic targets for these conditions.

Siltartoxatug is a human monoclonal antibody of the IgG1κ subtype, specifically designed to target tetanus toxin. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

PY314 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Triggering Receptor Expressed on Myeloid cells 2 (TREM2). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), offering potential applications in targeted cancer therapy.

Anti-E-Selectin Antibody (CL2) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target human E-Selectin. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG2a kappa Isotype Control. This antibody is ideal for researchers studying cellular adhesion processes, inflammation, and vascular biology.

The Anti-Matriptase Antibody is a human-derived monoclonal antibody, expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Matriptase. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is ideal for research applications focusing on the biological role and pathological significance of Matriptase.

MB-66 (MAPP-66) is a fully human IgG1 monoclonal antibody designed for vaginal application, specifically targeting HSV (Herpes Simplex Virus) and HIV (Human Immunodeficiency Virus). This product is presented as a monoclonal antibody film, optimizing local delivery and bioavailability at the site of viral entry. For experimental controls, MB-66 utilizes Human IgG1 kappa as its isotype control, ensuring specificity and reliability in research applications.

Ranibizumab (RG-6321), a humanized monoclonal antibody fragment, targets and inhibits vascular endothelial growth factor A (VEGF-A), recognizing all its isoforms including VEGF110, VEGF121, and VEGF165. This anti-VEGF agent is effective in slowing vision loss in vivo and is primarily utilized in research focused on wet age-related macular degeneration (AMD).

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein involved in the regulation of bone metabolism. By inhibiting sclerostin, Romosozumab enhances bone formation and decreases bone resorption, making it a valuable tool for investigating the pathophysiology and potential treatments of osteoporosis. This antibody is specifically designed for use in research applications focused on bone density disorders and related metabolic bone diseases.

Atoltivimab (REGN3470), also known as maftivimab/odesivimab under the brand name Inmazeb, is distinguished as the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for targeting Zaire ebolavirus (EBOV) infections. This therapeutic agent is specifically designed to neutralize the virus, providing a critical tool in the management and treatment of Ebola virus disease.

The Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody specifically designed to target Dectin-1, a key receptor involved in the recognition of β-glucans on pathogens, thereby playing a crucial role in the immune response against fungal infections. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for use in research focused on immune system responses, particularly in the study of fungal pathogenesis and innate immunity.

Lodapolimab (LY3300054) is an IgGλ monoclonal antibody that targets the programmed cell death protein 1 (PD-1). This antibody is designed to inhibit the PD-1 signaling pathway, which may enhance the immune system's ability to fight cancer.

Olendalizumab (ALXN1007) is a humanized monoclonal antibody derived from mouse IgG2-G4-κ, specifically designed to target Complement protein C5a with a dissociation constant (Ki) of 60 pM. This antibody plays a crucial role in modulating the complement inflammatory pathway. Olendalizumab is primarily utilized in research focused on complement-mediated disorders, particularly those associated with coronavirus infections. This specificity and application make it a valuable tool for studies aimed at understanding and potentially mitigating the impact of complement system dysregulation in viral diseases.